Global Gonadotropin-releasing Hormone Antagonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Gonadotropin-releasing Hormone Antagonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Gonadotropin-releasing hormone antagonists are used to treat advanced prostate cancer. They are also used to treat certain gynecologic conditions and are being studied in the treatment of hormone-sensitive breast cancer. Also called GnRH antagonist, LHRH antagonist, and luteinizing hormone-releasing hormone antagonist.
Gonadotropin-releasing Hormone Antagonists report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gonadotropin-releasing Hormone Antagonists market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Prostate Cancer and Endometriosis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Gonadotropin-releasing Hormone Antagonists industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Gonadotropin-releasing Hormone Antagonists key manufacturers include AbbVie, Takeda, Astellas, Kissei, Veru Inc, Myovant Sciences, AstraZeneca, Ferring Pharmaceuticals and Jiangsu Hengrui Medicine Co, etc. AbbVie, Takeda, Astellas are top 3 players and held % sales share in total in 2022.
Gonadotropin-releasing Hormone Antagonists can be divided into Peptides and Small Molecules, etc. Peptides is the mainstream product in the market, accounting for % sales share globally in 2022.
Gonadotropin-releasing Hormone Antagonists is widely used in various fields, such as Prostate Cancer, Endometriosis, Uterine Fibroids and Female Infertility, etc. Prostate Cancer provides greatest supports to the Gonadotropin-releasing Hormone Antagonists industry development. In 2022, global % sales of Gonadotropin-releasing Hormone Antagonists went into Prostate Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gonadotropin-releasing Hormone Antagonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AbbVie
Takeda
Astellas
Kissei
Veru Inc
Myovant Sciences
AstraZeneca
Ferring Pharmaceuticals
Jiangsu Hengrui Medicine Co
Segment by Type
Peptides
Small Molecules
Prostate Cancer
Endometriosis
Uterine Fibroids
Female Infertility
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Gonadotropin-releasing Hormone Antagonists market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gonadotropin-releasing Hormone Antagonists, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gonadotropin-releasing Hormone Antagonists industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Gonadotropin-releasing Hormone Antagonists in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gonadotropin-releasing Hormone Antagonists introduction, etc. Gonadotropin-releasing Hormone Antagonists Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Gonadotropin-releasing Hormone Antagonists market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Gonadotropin-releasing Hormone Antagonists report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gonadotropin-releasing Hormone Antagonists market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Prostate Cancer and Endometriosis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Gonadotropin-releasing Hormone Antagonists industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Gonadotropin-releasing Hormone Antagonists key manufacturers include AbbVie, Takeda, Astellas, Kissei, Veru Inc, Myovant Sciences, AstraZeneca, Ferring Pharmaceuticals and Jiangsu Hengrui Medicine Co, etc. AbbVie, Takeda, Astellas are top 3 players and held % sales share in total in 2022.
Gonadotropin-releasing Hormone Antagonists can be divided into Peptides and Small Molecules, etc. Peptides is the mainstream product in the market, accounting for % sales share globally in 2022.
Gonadotropin-releasing Hormone Antagonists is widely used in various fields, such as Prostate Cancer, Endometriosis, Uterine Fibroids and Female Infertility, etc. Prostate Cancer provides greatest supports to the Gonadotropin-releasing Hormone Antagonists industry development. In 2022, global % sales of Gonadotropin-releasing Hormone Antagonists went into Prostate Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gonadotropin-releasing Hormone Antagonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AbbVie
Takeda
Astellas
Kissei
Veru Inc
Myovant Sciences
AstraZeneca
Ferring Pharmaceuticals
Jiangsu Hengrui Medicine Co
Segment by Type
Peptides
Small Molecules
Segment by Application
Prostate Cancer
Endometriosis
Uterine Fibroids
Female Infertility
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Gonadotropin-releasing Hormone Antagonists market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gonadotropin-releasing Hormone Antagonists, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gonadotropin-releasing Hormone Antagonists industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Gonadotropin-releasing Hormone Antagonists in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gonadotropin-releasing Hormone Antagonists introduction, etc. Gonadotropin-releasing Hormone Antagonists Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Gonadotropin-releasing Hormone Antagonists market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices